Loading stock data…
IMA
$5.55-0.05 (-0.89%)
After Hours$5.55+0.00 (+0.00%)· Last close Jun 9
ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
ImageneBio, Inc. in the Healthcare sector is trading at $5.55 with a market capitalization of $61M. Wall Street consensus targets $24.00 (1 analysts), implying a +332.4% move over the next 12 months. The stock is currently near its 52-week low of $3.94, remaining 21.2% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +332.4% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$5.55
Potential Downside
0%
Whystock Fair Value$5.55
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus1 analysts
Mean target$24.00+332.4%
Range$24.00 – $24.00
Fundamentals
ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$61.47M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-39.23%
Volume
Today's trading volume
7,224
Recent News
Image Resources NL (ASX:IMA) Is About To Turn The Corner
With the business potentially at an important milestone, we thought we'd take a closer look at Image Resources NL's...
Imax announces $28M opening weekend for Amazon/MGM/s ‘Project Hail Mary’
IMAX (IMAX) Corporation announces the opening weekend for Amazon (AMZN) / MGM Studies’ “Project Hail Mary,” with IMAX delivering $28M at the global box office. The latest Filmed For IMAX release from Amazon/MGM, “Project Hail Mary” delivered $16.4 million in IMAX at the Domestic box office – 20% of the film’s North American debut on just 1% of screens in the market. “‘Project Hail Mary’ is an excellent film for which Amazon/MGM ran a brilliant campaign, leaning heavily on the power of IMAX as a
ImageneBio Insider Confidence Rewarded, Stock Hits US$76m Market Cap
ImageneBio, Inc. ( NASDAQ:IMA ) insiders who purchased shares in the last 12 months were richly rewarded last week. The...
Here's Why We're Watching ImageneBio's (NASDAQ:IMA) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Wall Street Analysts Believe IMAGENEBIO INC (IMA) Could Rally 695.48%: Here's is How to Trade
The consensus price target hints at a 695.5% upside potential for IMAGENEBIO INC (IMA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.